Previous 10 | Next 10 |
home / stock / chgcy / chgcy news
Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...
DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...
Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q2 2023
2023-07-27 17:44:28 ET Chugai Pharmaceutical press release ( OTCPK:CHGCF ): 1H GAAP EPS of ¥95.23. Revenue of ¥579.66B (-2.7% Y/Y). For further details see: Chugai Pharmaceutical GAAP EPS of ¥95.23, revenue of ¥579.66B
Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain PR Newswire The companies have entered a partnership agreement to develop new digital solutions for the objective assessment and management of pain associated wi...
Morgan Stanley says that global obesity sales in 2030 could reach $54B, driven by Eli Lilly ( NYSE: LLY ) and Novo Nordisk’s ( NVO ) ( OTCPK:NONOF ), while other large-cap pharma players closely watch their dominance amid emerging data from new biotechs. Obesi...
Chugai Pharmaceutical press release (OTCPK:CHGCF): Q1 GAAP EPS of ¥80.09. Revenue of ¥360.6B (+113.6% Y/Y). For further details see: Chugai Pharmaceutical reports Q1 results
The following slide deck was published by Chugai Pharmaceutical Co., Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Chugai Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation
AstraZeneca (NASDAQ:AZN) will pay $775M to Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) unit Chugai Pharmaceutical (OTCPK:CHGCF) to resolve all patent disputes related to rare disease drug Ultomiris. AstraZeneca had inherited the rare disease drug Ultomiris after acquiring Alexion Pharmaceuticals...
Roche (OTCQX:RHHBY) is closing a patent infringement suit against AstraZeneca (NASDAQ:AZN) related to the rare disease medicine Ultomiris, Fierce Pharma reported. AstraZeneca had inherited the rare disease drug Ultomiris after acquiring Alexion Pharmaceuticals. Roche’s C...
News, Short Squeeze, Breakout and More Instantly...
Chugai Pharmaceuticals Co. Ltd. ADR Company Name:
CHGCY Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
IDW Media Holdings, Inc. (IDWM) is expected to report for quarter end 2023-10-31 Deluxe Corporation (DLX) is expected to report $0.62 for Q4 2023 SkyWest Inc. (SKYW) is expected to report $0.11 for Q4 2023 1-800-FLOWERS.COM Inc. (FLWS) is expected to report $1.22 for Q2 2024 Brook...
Grandsouth Bancorporation (GRRB) is expected to report for quarter end 2023-09-30 Cadence Bank (CADE) is expected to report $0.56 for Q3 2023 Enterprise Financial Services Corporation (EFSC) is expected to report $1.24 for Q3 2023 Blackhawk Bancorp Inc. (BHWB) is expected to report fo...